Westside Investment Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $335K | Sell |
6,140
-100
| -2% | -$5.27K | 0.04% | 245 |
|
|
2026
Q1 | $299K | Buy |
6,240
+100
| +2% | +$5.27K | 0.05% | 246 |
|
|
2025
Q4 | $323K | Buy |
6,140
+100
| +2% | +$5.99K | 0.05% | 218 |
|
|
2025
Q3 | $393K | Sell |
6,040
-950
| -14% | -$54.5K | 0.06% | 206 |
|
|
2025
Q2 | $340K | Sell |
6,990
-952
| -12% | -$36.8K | 0.06% | 199 |
|
|
2025
Q1 | $269K | Buy |
7,942
+1,790
| +29% | +$75.9K | 0.06% | 202 |
|
|
2024
Q4 | $242K | Sell |
6,152
-290
| -5% | -$13.7K | 0.05% | 210 |
|
|
2024
Q3 | $308K | Sell |
6,442
-1,021
| -14% | -$51.8K | 0.07% | 187 |
|
|
2024
Q2 | $403K | Buy |
7,463
+70
| +0.9% | +$4.05K | 0.09% | 156 |
|
|
2024
Q1 | $504K | Buy |
7,393
+332
| +5% | +$23.8K | 0.12% | 143 |
|
|
2023
Q4 | $442K | Buy |
7,061
+50
| +0.7% | +$2.76K | 0.11% | 150 |
|
|
2023
Q3 | $318K | Hold |
7,011
| – | – | 0.09% | 167 |
|
|
2023
Q2 | $394K | Sell |
7,011
-119
| -2% | -$6.75K | 0.11% | 155 |
|
|
2023
Q1 | $322K | Sell |
7,130
-600
| -8% | -$29.1K | 0.09% | 169 |
|
|
2022
Q4 | $27.3K | Hold |
7,730
| – | – | 0.07% | 153 |
|
|
2022
Q3 | $43.6K | Hold |
7,730
| – | – | 0.1% | 133 |
|
|
2022
Q2 | $44.1K | Sell |
7,730
-200
| -3% | -$11.8K | 0.1% | 134 |
|
|
2022
Q1 | $44.1K | Buy |
7,930
+270
| +4% | +$17K | 0.1% | 134 |
|
|
2021
Q4 | $44K | Buy |
7,660
+3,910
| +104% | +$342K | 0.1% | 132 |
|
|
2021
Q3 | $43.8K | Buy |
3,750
+840
| +29% | +$105K | 0.1% | 130 |
|
|
2021
Q2 | $39.3K | Buy |
2,910
+100
| +4% | +$12.2K | 0.09% | 133 |
|
|
2021
Q1 | $29.6K | Buy |
2,810
+2,510
| +837% | +$379K | 0.08% | 132 |
|
|
2020
Q4 | $30.6K | Sell |
300
-100
| -25% | -$11.8K | 0.08% | 116 |
|
|
2020
Q3 | $25.1K | Sell |
400
-212
| -35% | -$18.8K | 0.01% | 120 |
|
|
2020
Q2 | $22.1K | Sell |
612
-250
| -29% | -$14.6K | 0.01% | 103 |
|
|
2020
Q1 | $25.5K | Buy |
+862
| New | +$44.5K | 0.02% | 112 |
|
|
2019
Q2 | $4 | Buy |
+100
| New | +$4K | ﹤0.01% | 564 |
|
|
2018
Q4 | $2.86K | Hold |
100
| – | – | ﹤0.01% | 604 |
|
|
2018
Q3 | $4.23K | Hold |
100
| – | – | ﹤0.01% | 609 |
|
|
2018
Q2 | $6K | Buy |
+100
| New | +$5.7K | ﹤0.01% | 653 |
|
|
2018
Q1 | – | Sell |
-100
| Closed | -$2.61K | – | 819 |
|
|
2017
Q4 | $2.61K | Hold |
100
| – | – | ﹤0.01% | 768 |
|
|
2017
Q3 | $1.97K | Hold |
100
| – | – | ﹤0.01% | 757 |
|
|
2017
Q2 | $1.6K | Hold |
100
| – | – | ﹤0.01% | 758 |
|
|
2017
Q1 | $1.99K | Buy |
+100
| New | +$1.96K | ﹤0.01% | 713 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Westside Investment Management's CRSP Position: Q2 2026 in Review
Westside Investment Management reduced its CRISPR Therapeutics (CRSP) stake by 1.6% in Q2 2026, selling an estimated $5.27K and leaving 6,140 shares worth $335K. The position accounts for 0.04% of the portfolio, ranked #245.
Westside Investment Management first reported a position in CRSP in Q1 2017 and has held it in 34 quarters since. The position peaked at $504K in Q1 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- Westside Investment Management held 6,140 shares of CRISPR Therapeutics worth $335K as of Q2 2026.
- Westside Investment Management sold 100 CRISPR Therapeutics shares in Q2 2026, an estimated $5.27K.
- CRISPR Therapeutics made up 0.04% of Westside Investment Management's portfolio in Q2 2026, its #245 holding.
- Westside Investment Management first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 34 quarters since.
- Westside Investment Management's CRISPR Therapeutics position peaked at $504K in Q1 2024.
- 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on Westside Investment Management's 13F filing for Q2 2026, filed 27 Jul 2026.